SMFM and the Preeclampsia Foundation to host President’s Workshop on Preeclampsia
The Society for Maternal-Fetal Medicine (SMFM) will partner with the Preeclampsia Foundation to host the President’s Workshop on Preeclampsia during SMFM’s 41st Annual Pregnancy Meeting, being held virtually today through Saturday.
The Society for Maternal-Fetal Medicine (SMFM) will partner with the Preeclampsia Foundation to host the President’s Workshop on Preeclampsia from Jan. 25-26. This two-day workshop will offer an in-depth look at how practitioners can predict, prevent, and manage preeclampsia in pregnancy.
The workshop will cover a wide range of relevant topics, including how to better determine at-risk mothers, implications on future cardiovascular health, impacts on long-term mental health, and more. Spreading awareness is crucial, says Preeclampsia Foundation CEO Eleni Z. Tsigas, because many preeclampsia symptoms can occur during a healthy pregnancy which can cause them to be overlooked.
The partnering organizations will also host a Twitter chat, “Let’s Talk about Pregnancy Complications,” with the parenting website BabyCenter, on Jan. 26 at 3 p.m. EST. Women will share personal stories to help spread awareness of preeclampsia and advocate critical warning signs.
For additional coverage of SMFM’s 2021 Virtual Annual Meeting, visit our Conference Coverage page. Interested participants can register for the conference via this link.
Contemporary OB/GYN Senior Editor Angie DeRosa gets insight on the current state of COVID-19 from Christina Han, MD, division director of maternal-fetal medicine at the University of California, Los Angeles, and member of its COVID-19 task force. Han is an active member of the Society for Maternal-Fetal Medicine and discusses the issues on behalf of SMFM.
Listen
Exogenous hormones and patients at increased risk for breast cancer
October 17th 2023This lecture, presented by Holly J. Pederson, MD, at The Menopause Society 2023 Annual Meeting, looked at combined oral contraceptives in BRCA carriers and other high-risk patients, and hormone therapy in postmenopausal gene carriers as well as other high-risk women.
Read More
